Louisiana State University Health Sciences Center in New Orleans

lsuhsc.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

71

Active

11

Phase 3

6

Total enrollment

7,632

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Human papillomavirus 9-valent vaccine, recombinant1
human papillomavirus vaccine, recombinant1
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%1
Balanced salt solution1
Semaglutide1
Phentermine-Topiramate combination1
Phentermine1
Tirzepatide1
Topiramate1
Diethylpropion1
Naltrexone/Bupropion1
Liraglutide1

Next readouts

  • 2022-12-30
  • 2025-12
  • 2026-01-30

Top conditions

  • Pulmonary Hypertension4
  • Dental Caries4
  • Multiple Sclerosis3
  • Scleroderma2
  • Systemic Sclerosis2
  • HIV Infections2
  • Hypertension2
  • Quality of Life2

Frequently asked questions about Louisiana State University Health Sciences Center in New Orleans

How many clinical trials does Louisiana State University Health Sciences Center in New Orleans have on ClinicalTrials.gov?
Louisiana State University Health Sciences Center in New Orleans is listed as the lead sponsor on 71 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
How many of Louisiana State University Health Sciences Center in New Orleans's trials are in Phase 3?
6 of Louisiana State University Health Sciences Center in New Orleans's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does Louisiana State University Health Sciences Center in New Orleans focus on?
Louisiana State University Health Sciences Center in New Orleans's most-studied conditions on ClinicalTrials.gov are Pulmonary Hypertension, Dental Caries, Multiple Sclerosis, Scleroderma, Systemic Sclerosis.
When are Louisiana State University Health Sciences Center in New Orleans's next clinical trial readouts?
Louisiana State University Health Sciences Center in New Orleans has 3 upcoming primary-completion readouts tracked here; the soonest is “Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?”, expected around 2022-12-30.